Jun 13, 2025, 07:54
3-Year Outcomes of AAV Gene Therapy in Hemophilia B: Study Published in NEJM Shows Long-Term Factor IX Expression
The New England Journal of Medicine posted on X:
“Liver-targeting adeno-associated virus–mediated gene therapy led to stable long-term factor IX expression and a decrease in bleeding episodes for up to 13 years in 10 men with hemophilia B. Full study results.”
Title: Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
Authors: Ulrike M. Reiss, Andrew M. Davidoff, Edward G.D. Tuddenham, Pratima Chowdary, Jenny McIntosh, Vincent Muczynski, Malo Journou et al.
Check the full article here.
Learn the latest news on Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology